Related Experiment Videos
Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young
1Division of Cardiology, King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden.
Insights
Tissue factor pathway inhibitor (TFPI) activity is elevated in young men post-myocardial infarction, particularly those with hypertriglyceridaemia. Increased TFPI correlates with dense LDL and HDL3b particles, suggesting links to coronary heart disease risk.
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Hemostasis
Background:
- Premature coronary heart disease (CHD) is a significant health concern.
- Hyperlipidaemia and altered coagulation pathways are implicated in CHD pathogenesis.
- Tissue factor pathway inhibitor (TFPI) plays a role in regulating blood coagulation.
Purpose of the Study:
- To investigate TFPI activity in young male post-myocardial infarction patients compared to controls.
- To explore the relationship between TFPI activity and plasma lipoproteins.
- To examine the coordinate regulation of factor VII and TFPI in hyperlipidaemia and premature CHD.
Main Methods:
- Quantification of TFPI activity and factor VII antigen (VIIag) in two patient cohorts and control subjects.
- Fasting and post-oral fat load investigations.
- Analysis of TFPI activity in relation to lipoprotein phenotypes, including dense LDL and HDL subspecies.
Main Results:
- Basal TFPI activity and VIIag levels were significantly increased in post-infarction patients.
- Elevated TFPI and VIIag were primarily observed in patients with hypertriglyceridaemic lipoprotein phenotypes.
- Increased TFPI activity strongly correlated with plasma levels of dense low-density lipoprotein (LDL) particles and HDL3b subspecies.
Conclusions:
- Young male post-myocardial infarction patients exhibit elevated TFPI activity, linked to specific lipoprotein profiles.
- The findings suggest a potential role for TFPI and lipoprotein interactions in the development of premature CHD.
- Further research is warranted to elucidate the precise mechanisms of TFPI regulation in hyperlipidaemia and CHD.
Abstract:
Tissue factor pathway inhibitor (TFPI) activity was quantified in two cohorts of young male post-infarction patients and in population-based control subjects to explore the relationships between TFPI activity and plasma lipoproteins and to address the issue of coordinate regulation of factor VII and TFPI in hyperlipidaemia and premature coronary heart disease (CHD). Participants were investigated in the fasting state and after an oral fat load. Basal TFPI activity and factor VII antigen (VIIag) levels were found to be increased in the patients (TFPI activity 1.25 +/- 0.23 vs 1.17 +/- 0.20 U/ml, p < 0.05; VIIag 537.7 +/- 127.7 vs 479.4 +/- 93.4 ng/ml, p < 0.001). The parallel increase was accounted for by patients with hypertriglyceridaemic lipoprotein phenotypes. In contrast, the level of activated factor VII (VIIa) neither differed significantly between patients and controls, nor between patients with different lipoprotein phenotypes. The elevated TFPI activity in the patients was closely associated with the plasma level of dense low density lipoprotein (LDL) particles (r = 0.46, p < 0.001) and with the plasma concentration of the small, dense high density lipoprotein (HDL) subspecies HDL3b (r = 0.34, p < 0.01).